`UNIVERS!TET
`
`V Organisation and staff
`
`Uppsala University Organisation and staff
`
`—nna sida pa Svenska
`
`f"\
`
`Kjell Oberg
`
`Professor at Department of Medical Sciences, Endocrin Oncology
`
`CONTACT INFORMATION
`
`Department of Medical Sciences, Endocrin Oncology
`
`Email:
`
`K'el|.Ober medsci.uu.se
`
`Telephone:
`+4618-6114917
`
`Mobile phone:
`+46 70 4250688
`
`Fax:
`
`West-Ward Pharm.
`Exhibit 1058
`Page 001
`
`
`
`O18-507268
`
`Visiting address:
`
`Room UAS |ng:40, Tr:5 Klin. forsk. avd. 2, lngéng 70, 3 tr.
`
`Postal address:
`
`Akademiska sjukhuset, Ing 40, 5 tr.
`SE-751 85 UPPSALA
`Sweden
`
`_ Medarbetarportalen (log in)
`
`PERSONAL MERITS
`
`MD, 6ver|ak., dekanus
`
`BIOGRAPHY
`
`Dr. Kjell Oberg is Professor of Endocrine Oncology at the Medical Faculty of Uppsala
`
`University. He was the former head of the Department of Endocrine Oncology,
`
`University Hospital, and he is a specialist in endocrinology and internal medicine. He
`
`founded the Dept. of Endocrine Oncology at Uppsala University Hospital and has 30
`
`years experience in the field of neuroendocrine tumors. Between 1986 and 1992 he was
`
`clinical associate director of the Ludwig Institute for Cancer Research. From 1998 to
`
`2002 he was chairman of the Department of Medical Sciences at the Medical Faculty of
`
`Uppsala University. Since July 2002 until June 2008 he has been the Dean of the
`
`Medical Faculty. He is the chairman of Centre of Excellence of Endocrine Tumors and
`
`Vice chairman of the Department of Endocrine Oncology, University Hospital, Uppsala.
`
`Currently Adjunct Professor of Surgery at Vanderbilt University, Nashville, US.
`
`Dr. Oberg was one of the founders and coordinator of the European Neuroendocrine
`
`Tumor Network (ENET) 1995-2000 and was past chairman of the Nordic
`
`Neuroendocrine Tumour Group. He has pioneered the treatment of carcinoid tumor
`
`patients with interferon and somatostatin analogues and developed assays for tumor
`
`markers such as Chromogranin A and radiological procedures including specialized PET
`scans.
`
`West-Ward Pharm.
`Exhibit 1058
`Page 002
`
`
`
`In 1988 he was the first to describe a genetic deletion in multiple endocrine neoplasia
`
`Type 1 (MEN1). Dr Oberg has given many hundreds of presentations at international
`
`meetings and published more than 500 papers within his research field, H-factor 64 and
`
`more than 12,000 citations. In addition he is the author of numerous chapters on
`
`Carcinoid tumors in several international textbooks including Wi/liam’s Textbook of
`
`Endocrinology, Leslie de Groot’s Textbook of Endocrinology, Clinical Endocrinology and
`
`Fordtran’s Textbook of Gastroenterology. Dr. Oberg is Editor-in Chief of World Journal of
`
`Gastroenterolgy (WJG).
`
`In 1991 Dr. Oberg received the European Interferon Research reward. In 2003 he
`
`received the award “Eminent Scientist Year 2003” by the International Research
`
`Promotion Council (IRPC) and World Scientist Forum and in 2004 he was awarded the
`
`European Gold Medal in Endocrinology from the English Endocrine Society. In
`
`November 2006 he received the Harry Bostrom Award Lecture at Swedish Medical
`
`Society. The University Hospital Clinical Research Award in 2011.
`
`Dr. ("Dberg is a member of the Royal Society of Sciences, member of Swedish Society of
`
`Medical Research, Honorary member of Finnish Oncology Society, Finnish Endocrine
`
`Society and Honorary member of Spanish Neuroendocrine NET-work. Dr. Oberg is
`
`Chairman Elect of ENETS and also a member of NANETS Advisory Board as well as
`
`several other national and international research and scientific boards and many
`
`scientific journal review boards.
`
`Show less
`
`CONTACT US
`
`Te|.: +46 (0)18—471 00 00
`
`MoLe_c_oma_c1_d_e_ta_il_s
`
`Universit Directo
`
`West-Ward Pharm.
`Exhibit 1058
`Page 003
`
`
`
`Kjell Oberg - Uppsala University, Sweden
`
`http://kata1og.uu.se/empinfo/?1anguageId=1&id=n96-5147[6/26/2015 4:46:44 PM]
`
`West-Ward Pharm.
`Exhibit 1058
`Page 004
`
`